Core Insights - Several small-cap healthcare and biotech companies experienced significant price increases in after-hours trading following earnings updates or upcoming financial disclosures [1] Company Summaries - MacroGenics, Inc. (MGNX) saw a 10.2% rise to $1.62 after hours, recovering from a 3.29% decline during the regular session. The company reported a third-quarter net income of $16.8 million, or $0.27 per share, down from $56.3 million, or $0.90 per share, year-over-year. Revenue fell to $72.8 million from $110.7 million [2] - SELLAS Life Sciences Group, Inc. (SLS) advanced 9.4% to $1.63 in after-hours trading. The company narrowed its quarterly net loss to $6.8 million, or $0.06 per share, compared to $7.1 million, or $0.10 per share, in the prior-year quarter. As of September 30, 2025, SELLAS reported cash and equivalents of approximately $44.3 million [3] - Standard BioTools Inc. (LAB) increased by 4.24% to $1.23 after hours, despite no official press releases or updates on Wednesday. The stock had closed slightly lower during the regular session [4] - KORU Medical Systems, Inc. (KRMD) gained 8.47% to $4.10 after hours, following a 1.34% increase earlier in the day. The company reported a narrower net loss of $0.8 million for the third quarter, compared to $1.6 million in the prior-year period. Revenue rose 27.2% to $10.4 million. KORU also raised its full-year revenue guidance to a range of $40.5 million - $41.0 million and reaffirmed its gross margin outlook of 61%-63% [5] - Hyperfine, Inc. (HYPR) climbed 8.18% to $1.19 after hours. No new announcements were made on Wednesday, but the company is scheduled to release its third-quarter results on Thursday, with analysts anticipating a loss of $0.10 per share and revenue of $3.52 million [6] - Wave Life Sciences Ltd. (WVE) added 5.68% to reach $7.35 in after-hours trading. The company reported a third-quarter net loss of $53.9 million, an improvement from $61.8 million in the prior-year quarter. Revenue for the period was $7.6 million, compared to a negative revenue figure of ($7.7) million last year [7]

Exhibit 99.1 SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Recent Corporate Highlights: Phase 3 REGAL Trial of GPS: Following the positive IDMC recommendation announced in August to continue the trial without modification, the Phase 3 REGAL trial of GPS in patients with acute myeloid leukemia (AML) who have achieved complete remission following second-line salvage therapy (CR2) remains on track and continues to execute as planned. The final analysis will be ...

Core Insights - SELLAS Life Sciences Group, Inc. reported positive developments in its clinical programs, particularly for SLS009 and GPS, with significant upcoming milestones and a strong financial position [1][2][3] Financial Performance - As of September 30, 2025, the company had cash and cash equivalents totaling approximately $44.3 million, with an additional $29.1 million received from warrant exercises in October 2025 [1][11] - Research and development expenses for Q3 2025 were $4.2 million, a decrease from $4.4 million in Q3 2024, primarily due to reduced clinical trial expenses [8] - General and administrative expenses for Q3 2025 were $2.9 million, slightly down from $3.0 million in Q3 2024, attributed to lower professional fees [9] - The net loss for Q3 2025 was $6.8 million, or a loss per share of $0.06, compared to a net loss of $7.1 million, or $0.10 per share, in Q3 2024 [10][16] Clinical Developments - The Phase 3 REGAL trial of GPS is progressing as planned, with a final analysis expected by year-end 2025 after reaching 80 events [3] - Positive Phase 2 data for SLS009 in relapsed/refractory AML has been accepted for presentation at the ASH Annual Meeting in December 2025, with plans for an 80-patient trial in newly diagnosed AML patients expected to start in Q1 2026 [4][6] - Preclinical data presented at ESMO 2025 showed significant survival benefits of SLS009 in T-cell prolymphocytic leukemia (T-PLL), supporting its potential across various hematologic malignancies [5] Corporate Events - A virtual R&D Day was held on October 29, 2025, showcasing the company's ongoing clinical trials and receiving positive feedback from key opinion leaders [6] - The company raised approximately $54.6 million in gross proceeds from warrant exercises in September and October 2025, enhancing its financial foundation [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________ FORM 10-Q ________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 001-33958 Delaware ...

Core Insights - The article discusses the impact of fake news on publicly traded companies, highlighting a recent incident involving Papa John's International Inc. and comparing it to past cases of market manipulation through false reports [1]. Group 1: Papa John's Incident - A false report claimed a $65-per-share acquisition offer from TriArtisan Capital Advisors, leading to significant stock volatility for Papa John's [8]. - The stock rose 18% intraday but ultimately settled 7.04% higher at $43.97, with a subsequent after-hours decline of 0.38% [8]. - Year-to-date, the stock has advanced 1.59%, but it has fallen 17.63% over the year [8]. Group 2: Vinci SA Case - In November 2016, Vinci SA's stock plummeted over 18% due to a fake press release claiming the firing of its CFO and the discovery of €3.5 billion in hidden losses [2][3]. - The company denied the claims, and the stock recovered, but the incident temporarily erased billions in market value [3]. Group 3: Avon Products Hoax - In May 2015, a fraudulent filing to the SEC claimed a non-existent firm intended to buy Avon Products for $18.75 per share, causing a 20% spike in stock price [4][5]. - The surge led to multiple trading halts before Avon confirmed the offer was false, revealing vulnerabilities in the SEC's filing system [5]. Group 4: Galena Biopharma Scheme - A 2017 SEC complaint detailed a "pump-and-dump" scheme involving Galena Biopharma, now Sellas Life Sciences Group Inc., where writers were paid to publish bullish articles, driving the stock price up by over 900% [6][7]. - This operation aimed to mislead both human investors and trading algorithms by creating the illusion of independent analyses [7].

Core Insights - Solaris Resources Inc. announced the results of a Pre-Feasibility Study (PFS) for its Warintza Project, highlighting a significant increase in mineral resources and the establishment of maiden mineral reserves [2][5][28] - The Warintza Project is positioned to capitalize on a tightening copper market, with exceptional economics and a strong community support framework [4][6][20] Mineral Resource and Reserves - The updated Mineral Resource Estimate (2025 MRE) includes 3.7 billion tonnes of Measured and Indicated Resources, 2.1 billion tonnes of Inferred Resources, and 1.3 billion tonnes of Mineral Reserves [5][26] - The 2025 MRE reflects a 312% increase in Measured plus Indicated Mineral Resources compared to the 2024 MRE, with significant new mineralization identified [26][39] Economic Metrics - The project is expected to generate an average annual copper equivalent production of over 300,000 tonnes in the first five years and over 240,000 tonnes during the first 15 years [7][14] - The post-tax net present value (NPV) is estimated at US$4,617 million, with a post-tax internal rate of return (IRR) of 26% [7][29] - Initial capital costs are projected at US$3.7 billion, with a payback period of 2.6 years post-tax [7][29] Production and Operating Costs - The average All-In Sustaining Cost (AISC) is projected at US$0.85 per pound of payable copper for the first five years and US$1.07 for the first 15 years [7][29] - The project will utilize conventional open-pit mining methods, with a low strip ratio of 0.53 to 1, enhancing its economic viability [24][46] Community and Environmental Engagement - The company has established formal agreements with local Indigenous communities, ensuring shared benefits and participatory decision-making [20][21] - Solaris maintains close engagement with government authorities to facilitate permitting and environmental assessments [22][36] Infrastructure and Accessibility - The Warintza Project benefits from strong existing infrastructure, including paved highways and proximity to ports, which supports efficient transportation of materials [19][58] - The power supply for the project will be sourced from a 62.1 km overhead transmission line, ensuring adequate energy for operations [59]

Core Insights - SELLAS Life Sciences Group, Inc. is advancing its late-stage clinical biopharmaceutical development, particularly focusing on SLS009 for relapsed or refractory acute myeloid leukemia (r/r AML) [1][2] - The Phase 2 study of SLS009 will be presented at the upcoming ASH Annual Meeting, highlighting its potential in combination with azacitidine and venetoclax [1][3] - The company emphasizes the growing evidence supporting SLS009's efficacy across hematologic malignancies, with preclinical data demonstrating its cytotoxic effects on AML cell lines [2][4] Company Overview - SELLAS is a late-stage clinical biopharmaceutical company dedicated to developing novel therapies for various cancer indications, with a lead product candidate, GPS, targeting the WT1 protein [4] - SLS009, a CDK9 inhibitor, is positioned as a potentially first-in-class treatment with reduced toxicity and increased potency compared to existing CDK9 inhibitors [4] - The company aims to address significant unmet needs in treating difficult-to-manage cancers, particularly in patients with unfavorable prognostic factors like ASXL1 mutations [4]

Core Points - SELLAS Life Sciences hosted an R&D Day to discuss advancements and future directions in their research and development efforts [1][2] - The agenda included opening remarks by the CEO, followed by discussions on the AML treatment landscape and the company's product offerings [2][3] Group 1: Company Overview - The company is focused on addressing unmet needs in the treatment of Acute Myeloid Leukemia (AML) [2] - GPS and SLS009 are positioned within the current standards of care for AML [2] Group 2: Research and Development - Dr. Omer Jamy provided context on the AML treatment landscape, highlighting areas of unmet need [2] - Dr. Panagiotis Tsirigotis and Dr. Dragan Cicic discussed the mechanism of action and differentiation of GPS, along with details of the Phase III REGAL trial [3]

Group 1 - Sellas Life Sciences Group Inc. announced the immediate exercise of warrants for 22.4 million shares, raising $31 million in gross proceeds [1][2] - The new warrants, priced at $2 per share, will be exercisable immediately and will expire five years from issuance [2] - The company is preparing for a virtual R&D Day on October 29, 2025, to discuss treatments for acute myeloid leukemia, including its lead product candidate GPS and SLS009, a CDK9 inhibitor [3][4] Group 2 - Sellas Life Sciences focuses on developing novel cancer therapies, with its lead candidate being galinpepimut-S (GPS), targeting the WT1 protein for various cancers [4] - SLS009 is being developed as a CDK9 inhibitor for certain types of leukemia, with preliminary results suggesting its potential role in treating T-cell prolymphocytic leukemia [3][4]

Summary of SELLAS Life Sciences Group R&D Day Company Overview - **Company**: SELLAS Life Sciences Group (NasdaqCM:SLS) - **Focus**: Development of innovative cancer therapies, specifically targeting acute myeloid leukemia (AML) with two main assets: Galinpepimut-S (GPS) and SLS009 Key Points and Arguments Industry Context - **AML Treatment Landscape**: Despite advancements in AML treatments, patient outcomes remain modest, indicating a significant unmet need for more effective therapies [14][15][21] - **Current Standards of Care**: Treatments include intensive chemotherapy, hypomethylating agents, and combinations with venetoclax, but many patients do not achieve remission or relapse quickly [15][18][20] Product Pipeline - **Galinpepimut-S (GPS)**: A WT1-targeted immunotherapy showing promising results in improving overall survival in AML patients, particularly in those who are in second remission or post-transplant [10][21][49] - **Clinical Data**: In earlier studies, GPS demonstrated a median overall survival of over 60 months in first remission and 21 months in second-line settings, significantly higher than standard care [21][31][49] - **SLS009 (Tebonciclib)**: A selective CDK9 inhibitor with potential applications in both hematologic malignancies and solid tumors [12][22] - **Clinical Data**: Showed improved survival rates in patients refractory to venetoclax, extending survival from 2-3 months to 8-9 months [22][29] Clinical Trials - **RIGEL Trial**: A phase 3 trial evaluating GPS in AML patients who are in remission but at high risk of relapse [10][11][54] - **Enrollment**: 126 patients randomized to receive GPS or best available therapy [53] - **Expected Outcomes**: The trial aims to demonstrate a significant improvement in overall survival compared to standard treatments, with a focus on hazard ratios as the primary endpoint [55][58] Financial Position - **Recent Funding**: Strengthened balance sheet with an additional $31 million from warrant exercises, enabling continued clinical development [5] Market Potential - **AML Market Size**: Approximately 77,000 new AML cases diagnosed annually in major markets, with a significant portion expressing WT1, making them potential candidates for GPS [60][61] - **Commercial Opportunity**: GPS and SLS009 are positioned to address critical gaps in current AML treatment paradigms, with GPS potentially becoming a first-in-class maintenance therapy [11][12] Unmet Needs - **Areas of Focus**: - Patients in second remission unable to undergo transplant - Patients refractory to venetoclax-based therapies - Need for effective maintenance strategies post-transplant [20][21][28] Scientific Rationale - **Mechanism of Action for GPS**: Targets WT1, which is overexpressed in AML, eliciting a strong immune response without affecting normal cells, thus avoiding myelosuppression [36][42][43] - **Immunogenicity**: GPS is designed to activate both CD8 and CD4 T cells, enhancing the immune response against leukemic cells [44][45] Conclusion - **Long-term Vision**: SELLAS is committed to transforming AML treatment through innovative therapies that extend patient survival and improve quality of life, with a strong focus on scientific integrity and patient impact [3][4][6]